ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association

Drug delivery and toxicity of adjuvant chemotherapy for non-small cell lung cancer (NSCLC): Washington University experience

“…Grade 3/4 neutropenia in our study occurred in 25% of the patients as opposed to 36% in the CALGB 9633 trial, 17.5% (grade 4 alone) in the IALT trial and 85% in the ANITA trial [2,4,7]. This report provides the first ''real life'' experience regarding the chemotherapy delivery and toxicity in patients with resected non-small cell lung cancer outside the context of clinical trials.…”

Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590

“…Following surgery alone, the 5-year survival for patients with pathological stage IB, II and IIIA NSCLC is still disappointing at 60%, 40-50% and 25%, respectively (2). Adjuvant chemotherapy with platinum-based doublets has been shown to improve survival in wellconducted randomized trials (3)(4)(5)(6). The overall 5-year survival improvement in these studies ranged from 5 to 15% (3,4,6).…”

“…Adjuvant chemotherapy with platinum-based doublets has been shown to improve survival in wellconducted randomized trials (3)(4)(5)(6). The overall 5-year survival improvement in these studies ranged from 5 to 15% (3,4,6). Despite the recognized association of clinical and pathologic characteristics (age, weight loss, performance status, tumor-node-metastasis staging system) with prognosis, these parameters alone do not predict which patients are prone to develop recurrent disease and do not identify patients who will benefit from adjuvant therapy (2,4,7).…”

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study

“…Results from randomised studies of early stage resectable non-small-cell lung cancer (NSCLC) have shown improved survival from use of adjuvant chemotherapy (Non-small Cell Lung Cancer Collaborative Group, 1995;Arriagada et al, 2004;Strauss et al, 2004;Winton et al, 2004;Douillard et al, 2005). Improvements in 5-year survival of 12 -15% have been observed with adjuvant platinum-based doublet regimens in early stage disease (stage IB -IIIA) (Strauss et al, 2004;Winton et al, 2004;Douillard et al, 2005), and adjuvant chemotherapy is now considered the standard of care after radical surgical resection. However, the associated toxicity and subjective poor tolerance of adjuvant chemotherapy are a major limitation.…”